Why is ATAI stock rising?

The stock surged 59% after Bloomberg reported that Eli Lilly is nearing an acquisition of the company.

Has the deal been officially announced?

No, the deal has not been officially announced. The report is based on sources familiar with the matter.

Eli Lilly Nears Acquisition of AtaiBeckley

Eli Lilly is nearing an acquisition deal with AtaiBeckley, according to a Bloomberg report. ATAI shares surged 59% in after-hours trading.

July 16, 2026

1 min read

Source: Stocktwits

Eli Lilly (LLY) is close to finalizing an acquisition of AtaiBeckley (ATAI), Bloomberg reported Wednesday, citing sources familiar with the matter. Specific terms, including the purchase price and timeline, have not been disclosed.

Deal Details

Buyer: Eli Lilly (LLY)
Target: AtaiBeckley (ATAI)
Value: Not disclosed
Premium: Not specified
Expected Close: Not announced

Rationale

Eli Lilly aims to bolster its mental health portfolio. AtaiBeckley focuses on developing novel treatments for psychiatric disorders using psychedelic compounds like psilocybin. The acquisition could give Lilly a foothold in a rapidly growing market.

Regulatory Hurdles

The deal may face regulatory scrutiny, as some of AtaiBeckley's products are still in clinical trials. The healthcare sector is heavily regulated.

Stock Impact

ATAI shares surged 59% in after-hours trading, reflecting investor optimism. LLY shares remained relatively unchanged. The positive momentum for ATAI may continue until an official announcement.

Frequently Asked Questions

AtaiBeckley is a company focused on developing treatments for psychiatric disorders using psychedelic compounds like psilocybin.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.